AlphAIAlphAI — Financial news for AI agents
securities.ioOCT 52 min read$GEHC

GE HealthCare Agrees to Buy SOFIE Biosciences for $945 Million

GE HealthCare (GEHC) agreed to acquire SOFIE Biosciences, a U.S. PET radiopharmaceutical manufacturer, for $945M in cash. The deal, expected to close in early 2027, will expand GEHC's pharmaceutical diagnostics segment. SOFIE operates 15 U.S. sites with 21 cyclotrons, enhancing GEHC's supply capabilities. The acquisition is expected to be accretive to revenue and earnings in the first full year.

Original reporting
securities.io
Published Oct 5, 2026, 12:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 12:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$GEHC
Bullish
high confidence
Mentioned
$GEHC
Relevance
9/10
AlphAI data visualization · based on securities.io
Decision brief

The 30-second read

$GEHCBullishHigh
01

Why it matters

The acquisition adds a final‑mile manufacturing capability, supporting growth in the fast‑expanding PET imaging market.

02

Market read

The deal is material for GEHC shareholders and may influence the broader diagnostic imaging sector.

03

What to watch

Regulatory approvals and potential antitrust review could delay or alter deal economics.

Relevance 9/10Novelty 9/10Timing: immediate – deal announced today

Background

GE HealthCare is expanding its pharmaceutical diagnostics business by acquiring a leading U.S. contract manufacturer of PET radiopharmaceuticals.

Company-level read

Ticker impact

$GEHCBullishHigh confidence
Context

GE HealthCare announced a $945 million cash acquisition of SOFIE Biosciences, expected to close in H1 2027.

Expected impact

likely modest upside as the market prices in the acquisition premium and growth potential

Evidence & confidence

Large‑cap M&A with clear financial benefits; investors typically reward such strategic expansions.

Market effects

Sector

Strengthens GE HealthCare's position in the PET radiopharmaceutical manufacturing sector.

Regional

Expands U.S. supply chain for F‑18 PET tracers, potentially boosting domestic manufacturers.

Global

May increase competition for European and Asian PET imaging firms as GE leverages its global footprint.

Counterpoint

What could challenge this read

The cash outlay could strain GEHC's balance sheet and integration risk may offset upside.

Key entities

  • company
    GE HealthCare

    U.S. health‑technology division of General Electric, listed as GEHC.

  • company
    SOFIE Biosciences

    U.S. contract manufacturer of PET radiopharmaceuticals.

Read at source← All news

Also covered by

6 outlets

Related articles

OCT 7
$GEHCHighAI 9/10

GE HealthCare to acquire SOFIE Biosciences for $945 million, expanding U.S. PET supply footprint

GE HealthCare will acquire SOFIE Biosciences for $945 million in cash, expanding its U.S. PET radiopharmaceutical supply. The deal, expected to close in early 2027, will add SOFIE's 15 manufacturing sites and 21 cyclotrons to GE HealthCare's Pharmaceutical Diagnostics segment, enhancing its theranostics capabilities and access to high-growth areas. SOFIE's FAPI-74 radiopharmaceutical is in Phase III trials.

gmtoday.com2 min
OCT 7
$GEHCHighAI 9/10

GE HealthCare Agreed to Buy Trilantic-Backed SOFIE Biosciences for $945 Million:

GE HealthCare agreed to buy SOFIE Biosciences, a U.S. contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal, expected to close in early 2027, includes SOFIE's 15 U.S. manufacturing sites and rights to FAPI-74, an experimental PET imaging agent. SOFIE will continue serving existing customers post-acquisition. Trilantic North America, SOFIE's private equity backer, sold the company to GE HealthCare, which aims to expand its pharmaceutical diagnostics segment.

hedgeco.net2 min